Hot High Dividend Companies To Invest In Right Now

Let�� take a look at high dividend paying ETFs that offer an opportunity for both growth and income. Growth & income exchange-traded funds typically run the gamut from all equity to balanced asset allocation options.

Should you own a growth and income ETF? Would it be better to own a solid growth ETF and solid income ETF? Is there an ETF that offers a bridge between the two?

Maybe. Often. Yes.

I have a growth and income bias toward owning ETFs with specific trajectories rather than simply opting for a blend. Furthermore, when looking at more equity-concentrated growth and income ETFs, my preference is for creative sources of income (dividends and convertibles) as opposed to the pure equity approach. (If I want pure equity, there are many ETFs in today�� market that can provide that.)

I think the right place to be now and over the next 10 years will generally be in equities, not at the exclusion of bonds, but not without being selective and flexible, strategic and tactical about the types of bonds you own, the role they play in your portfolio (as a stock market buffer and/or as a source of reliable income) and the duration that you hold one offering or another.

Best Clean Energy Companies To Invest In Right Now: Body Central Corp.(BODY)

Body Central Corp. operates as a specialty retailer of young women's apparel and accessories in the south, mid-Atlantic, and midwest regions of the United States. The company operates specialty apparel stores under the Body Central and Body Shop banners, as well as a direct business of its Body Central catalog and e-commerce Website at bodyc.com. Its stores feature an assortment of tops, dresses, bottoms, jewelry, accessories, and shoes under Body Central and Lipstick labels. As of March 8, 2012 it operated 241 specialty apparel stores in 24 states. The company, formerly known as Body Central Acquisition Corp., was founded in 1972 and is headquartered in Jacksonville, Florida.

Advisors' Opinion:

• [By Roberto Pedone]

   

  Body Central (BODY) operates apparel stores and also conducts direct business via catalogues and Web site. This stock closed up 3.8% to $3.52 in Tuesday's trading session.

   

  Tuesday's Range: $3.40-$3.55
  
  52-Week Range: $3.09-$13.39
  
  Tuesday's Volume: 475,000
  
  Three-Month Average Volume: 421,188

   

  From a technical perspective, BODY trended higher here right above some near-term support at $3.21 with above-average volume. This move pushed shares of BODY into breakout territory, since the stock took out some near-term overhead resistance at $3.50. This move is also coming off oversold territory, since BODY's current relative strength index reading is 29.89. Oversold can always get more oversold, but it's also an area where a stock can experience a powerful bounce from.

   

  Traders should now look for long-biased trades in BODY as long as it's trending above some key near-term support levels at $3.21 or at $3.09 and then once it sustains a move or close above Tuesday's high of $3.55 with volume that hits near or above 421,188 shares. If we get that move soon, then BODY will set up to re-test or possibly take out its next major overhead resistance levels at $4 to $4.50.

   

• [By Sally Jones]

  A high number of billionaire investors hold today�� featured apparel companies including American Eagle Outfitters (AEO), Urban Outfitters (URBN) and Body Central Corp. (BODY), as revealed by the GuruFocus 52-week low screener.

• [By Lee Jackson]

  Body Central Corp. (NASDAQ: BODY) also comes in with an off-the-charts IRR of 26%. The company reported a dreadful second quarter, which hammered the share price. Body Central operates as a specialty retailer of young women’s apparel and accessories in the South, Mid-Atlantic and Midwest regions of the United States. It operates stores under the Body Central and Body Shop banners, as well as a direct business comprising its Body Central catalog and e-commerce website at bodycentral.com. The company’s stores sell tops, dresses, bottoms, jewelry, accessories and shoes, primarily under its Body Central and Lipstick labels. The lower the share price goes, the more attractive the stock becomes. The consensus price target is $11, with the high target at $12. The stock closed Thursday at $6.43.

• [By DAILYFINANCE]

  Richard Drew/AP NEW YORK -- The stock market started November on a strong note as investors reacted to an expansion in U.S. manufacturing last month. The improvement came during what could have been a difficult month for the U.S. economy, with a partial government shutdown that lasted 16 days and a narrowly averted default on the U.S. government's debt, which could have rattled financial markets. "With what happened in the last two months, it's amazing how strong this market has been," said Bob Doll, chief equity strategist at Nuveen Asset Management. The Institute for Supply Management reported that its manufacturing index increased to 56.4, the highest level since April 2011. That was better than the 55.1 figure economists were expecting, according financial data provider FactSet. The Dow Jones industrial average (^DJI) rose 69.80 points, or 0.5 percent, to 15,615.55. The Standard & Poor's 500 index (^GPSC) rose 5.10 points, or 0.3 percent, to 1,761.64. The Nasdaq composite (^IXIC) rose 2.34 points, or 0.1 percent, to 3,922.04. Energy stocks lagged the market after Chevron (CVX) reported that its third-quarter income fell 6 percent, missing analysts' estimates, due to weakness in the company's oil refining business. Chevron fell $1.95, or 1.6 percent, to $118.01. The energy sector was also weighed down by a drop in the price of oil. Crude oil fell $1.77, or 1.8 percent, to $94.61 a barrel. The positive start to this month's trading comes after a strong October for the stock market. The S&P 500 closed at a record high seven times during the month, most recently on Tuesday. It ended October with a gain of 4.5 percent. However, some investors have expressed skepticism that stocks can keep up this rapid pace pace heading into the last two months of the year. The S&P 500 is up 23 percent so far this year, while the average annual return on the S&P 500 is around 8 percent. Stocks are also starting to look expensive by some measures. Investo

Hot High Dividend Companies To Invest In Right Now: Furiex Pharmaceuticals Inc (FURX)

Furiex Pharmaceuticals, Inc. is a drug development collaboration company. The Company�� product pipeline includes two marketed products and three programs in development, including late-stage compounds, in multiple therapeutic areas. Its programs include Priligy, Alogliptin Nesina, Alogliptin/Actose Combination, Alogliptin/Metformin Combination, Fluoroquinolone, Mu Delta and PPD 10558. In November 2011, it acquired full exclusive license rights to develop and commercialize the compound MuDelta under its existing development and license agreement with Janssen Pharmaceutica N.V.

Priligy (dapoxetine) is a drug developed for the on-demand treatment of premature ejaculation (PE). Dapoxetine is a short-acting, selective serotonin reuptake inhibitor (SSRI) designed to be taken only when needed one to three hours before sexual intercourse is anticipated rather than every day. Nesina (alogliptin) is a drug for the oral treatment of type 2 diabetes (T2D). Alogliptin is a DPP-4 inhibitor that slows the inactivation of incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP).

Fluoroquinolone drug candidate is a Phase II-ready novel fluoroquinolone antibiotic that is being developed by the Company for the treatment of complicated skin and skin structure infections, such as abscesses that occur deep in the skin layers and respiratory infections. This antibiotic has a spectrum of activity and is able to treat methicillin-resistant staphylococcus aureus (MRSA) infections. The Company is developing both oral and intravenous (IV) formulations. The Company is developing Mu Delta for treatment of diarrheal predominant irritable bowel syndrome (d-IBS). The Company is conducting a Phase II study on an oral formulation of Mu Delta.

The Company is developing PPD 10558 for the treatment of dyslipidemia. PPD 10558 has shown muscle safety in preclinical studies by minimizing the delivery of the drug to the muscle. The Company has filed an inve! stigational new drug (IND) application with the United States Food and Drug Association and completed five clinical studies.

Advisors' Opinion:

• [By Jake L'Ecuyer]

  Top Headline
  Forest Laboratories (NYSE: FRX) announced its plans to buy Furiex Pharmaceuticals (NASDAQ: FURX) for up to $1.46 billion. Forest will pay around $95 per share, or around $1.1 billion in cash. Forest Labs will also pay up to $30 per share, or around $360 million in a contingent value right. The deal is projected to close in the second or third quarter of 2014.

Hot High Dividend Companies To Invest In Right Now: NextStage Inc (NXT)

NextStage, Inc. is a holding company. The Company is engaged in the management of its investments in shares of stocks of its subsidiaries. The Company�� subsidiaries include Mondex Philippines Inc. (MXP), Infinit-e Asia Inc. (Infinit-e Asia) and Technology Support Services, Inc. (TSSI). MXP operates a multi-application smart card system in Philippines. Infinit-e Asia is a software development company specializing on smart card and e-commerce solutions tailored to enhance the business of its clients. Infinit-e Asia develops smart card solutions for both real and online applications and on both contact and contactless platform. Infinit-e Asia�� spectrum of products and applications are classified as payments, data capture and security. TSSI is engaged in the business of business process outsourcing (BPO), applications service providers (ASP) and managed service providers (MSP). Advisors' Opinion:

• [By Namitha Jagadeesh]

  HSBC Holdings Plc (HSBA), Europe�� largest bank, slid 2.1 percent. International Consolidated Airlines Group SA (IAG) declined 2 percent as it canceled some of its flights following a disruption caused by one of its planes at Heathrow airport. Next Plc (NXT) retreated 2.4 percent as Morgan Stanley cut its recommendation on the shares.

Hot High Dividend Companies To Invest In Right Now: Concho Resources Inc. (CXO)

Concho Resources Inc., an independent oil and natural gas company, engages in the acquisition, development, and exploration of producing oil and natural gas properties in the United States. Its operations are focused in the Permian Basin of Southeast New Mexico and West Texas. The company also has acreage positions in the Bakken/Three Forks play in North Dakota. As of December 31, 2010, Concho Resources had estimated proved reserves of 323.5 million barrel of oil equivalent. The company is headquartered in Midland, Texas.

Advisors' Opinion:

• [By Russ Krull]

  Concho Resources (NYSE: CXO  ) reopened an issue from last August and sold $850 million of 10-year, 5.5% paper. Concho got a better deal on this round, selling the paper at 103.75% of par, compared with even par last August. About $320 million of the new money is funding a tender offer for some higher-rate 2017 paper. The rest of the money goes toward paying down a credit facility and for general corporate purposes.

• [By Jim Jubak]

  Having done about all it could to increase US crude exports, by granting export licenses to Canada (permitted under the current system), I think the Obama administration is likely to move to grant new export licenses to countries other than Canada in 2014. That policy change would turn US oil producers into a rare bright spot in an energy sector that is looking at stable or falling global oil prices in 2014. Stocks I'd take a look at are Pioneer Natural Resources (PXD), Concho Resources (CXO) and Targa Resources Partners (NGLS). Pioneer Natural Resources is a member of my Jubak Picks 50 long-term portfolio. Targa Resources Partners is a member of my Jubak's Picks 12-18 month portfolio

• [By Lee Jackson]

  Concho�Resources Inc. (NYSE: CXO) CEO Tim Leach was enthusiastic about Concho�� recent growth in the Delaware Basin, which grew 37% quarter over quarter. The company also announced it is doubling its rig count in the Northern Delaware basin. The Raymond James price target is posted at $127, and the consensus target is $110.

• [By WWW.GURUFOCUS.COM]

  Concho Resources, Inc. (CXO) is an independent E&P company focused on the Permian Basin in West Texas. Concho shares rose in the first quarter as the company provided greater detail about a significant increase in its oil and gas resource potential across its acreage position in the Permian and particularly in the Delaware sub-basin. The combination of the increase in the company's drilling inventory, strong initial well results and a faster than expected acceleration in its drilling inventory bode well for Concho's production growth outlook and for improvements in its net asset value. (James Stone)

Hot High Dividend Companies To Invest In Right Now: Turkiye Garanti Bankasi AS (GARAN)

Turkiye Garanti Bankasi AS (the Bank) is a Turkey-based financial services company. The Bank provides retail, commercial, corporate and small and medium size enterprises (SME) banking, leasing, insurance, asset management and factoring services. Other operation heading under the banking segment include mainly treasury and investment banking activities as well as unallocated income and expense items. It has a network of 822 domestic branches, seven foreign branches, three representative offices abroad and 104 offices. In addition to its branches, the Bank has 100% ownership in three banks each of which is located in Amsterdam, Bucharest and Moscow. The Bank and its affiliates operate principally in Turkey, but also have operations in the Netherlands, Romania, Russia, Turkish Republic of Northern Cyprus, Malta, Luxembourg and Germany. Advisors' Opinion:

• [By Ian Sayson]

  Russia�� Micex Index declined, trimming its weekly gain to 2.5 percent. OAO Mechel, the nation�� biggest producer of coal for steelmakers, slumped 1.7 percent. The Borsa Istanbul National 100 Index sank 2 percent as Turkiye Garanti Bankasi AS (GARAN) led losses in lenders. Benchmark gauges in the Czech Republic and Hungary declined at least 1.2 percent.

Hot High Dividend Companies To Invest In Right Now: Domino's Pizza Inc(DPZ)

Domino?s Pizza, Inc., through its subsidiaries, operates as a pizza delivery company in the United States and internationally. The company sells and delivers pizzas under the Domino?s Pizza brand name. As of January 1, 2012, it operated through a network of 9,742 stores, including 394 company-owned stores and 9,348 franchise stores located in the 50 states and approximately 70 international markets. Domino?s Pizza, Inc. was founded in 1960 and is headquartered in Ann Arbor, Michigan.

Advisors' Opinion:

• [By Jayson Derrick]

  Analysts at Citigroup maintained a Neutral rating on Domino's Pizza (NYSE: DPZ) with a price target raised to $79 from a previous $77. Shares lost 2.11 percent, closing at $72.00.

• [By Jayson Derrick]

  Analysts at Jefferies maintained a Buy rating on Domino's Pizza (NYSE: DPZ) with a price target raised to $93 from a previous $85. Also analysts at Morgan Stanley maintained an Equal-Weight rating on Domino's with an $84 price target. Shares hit new 52-week highs of $84.73 before turning negative and closing the day at $83.65.

Best Biotech Companies To Watch For 2014

Popular Posts: 5 Oil and Gas Stocks to Buy Now17 Oil and Gas Stocks to Sell Now9 Biotechnology Stocks to Buy Now Recent Posts: 9 “Triple A” Stocks to Buy 16 Oil and Gas Stocks to Sell Now 7 Machinery Stocks to Buy Now View All Posts

This week, nine stocks get A’s (“strong buy”) in Portfolio Grader‘s three main grading categories, Total Grade, Overall Fundamental Grade and Quantitative Grade.

These are the best of the best in the entire Portfolio Grader database. This week, there are 4,279 stocks and only these nine get top marks in all categories to make the elite “Triple A” stocks list. Here they are:

Top 5 Prefered Stocks To Buy For 2015: Tonix Pharmaceuticals Holding Corp (TNXP)

Tonix Pharmaceuticals Holding Corp., incorporated on November 16, 2011, is a specialty pharmaceutical company focused on developing novel pharmaceutical products for disorders of the central nervous system (CNS). The Company develops TNX-102 sublingual tablet, or TNX-102 SL. TNX-102 SL is a novel dose and formulation of cyclobenzaprine (CBP), the active pharmaceutical ingredient of two prescribed muscle relaxant products, Flexeril and Amrix. TNX-102 SL is also intended for chronic use. It develops TNX-102 SL for the treatment of FM under a United States Investigational New Drug application (IND), and under three clinical trial applications (CTAs), filed in Canada. It also develops TNX-102 SL for the treatment of post-traumatic stress disorder (PTSD). As of January 25, 2013, the Company focuses on product development, and had not generated any revenues.

The Company searches for potential therapeutic solutions among known pharmaceutical agents that lack regulatory approval for the indications it seeks, but may be approved for use in other indications. It seeks to create new dose and formulation options that are tailored to the therapeutic uses to which it applies these agents. TNX-102 SL is a small, rapidly disintegrating tablet containing CBP for sublingual administration at bedtime. The Company designed TNX-102 SL for delivery of CBP to the systemic circulation through sublingual transmucosal absorption and to avoid first-pass liver metabolism.

CBP is the active pharmaceutical ingredient in its lead product candidate, TNX-102 SL. In addition to CBP, TNX-102 SL contains inactive ingredients, called excipients, which are approved for pharmaceutical use. In addition to TNX-102 SL, it develops other formulations of CBP, including TNX-102 promicellar gelatin capsule, or TNX-102 gelcap. It developed TNX-102 gelcap under an agreement with Lipocine, Inc. (Lipocine), a contract formulation developer and small-scale manufacturer. In addition it has other pipeline of other product cand! idates, including TNX-201 and TNX-301. TNX-201 is based on isometheptene mucate and is under development as a treatment for certain types of headaches.

Advisors' Opinion:

• [By John Kell]

  Tonix Pharmaceuticals Holding Corp.(TNXP) is planning to offer some shares to raise money to fund clinical trials and the continued development of the specialty pharmaceutical company’s treatments. Shares edged up 2.1% to $16.75 premarket.

• [By John Udovich]

  It�� a new year and the first one and a half trading weeks of 2014 has not disappointed biotech investors as the sector and mid cap or small cap biotech or�pharma stocks like Intercept Pharmaceuticals Inc (NASDAQ: ICPT), Epizyme Inc (NASDAQ: EPZM), Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) and TNI BioTech Inc (OTCQB: TNIB) either surging or producing some news plus there have been IPO filings for future listings for�Flexion Therapeutics (NASDAQ: FLXN), Aldexa Therapeutics (NASDAQ: ALDX), Retrophin (NASDAQ:�RTRX) and Dicerna Pharmaceuticals (NASDAQ: DRNA). Consider the following news so far this year:

Best Biotech Companies To Watch For 2014: Redhill Biopharma Ltd (RDHL)

Redhill Biopharma Ltd. is an Israel-based biopharmaceutical company. The Company is focused on the development and acquisition of therapeutic candidates. The Company�� pipeline consists of six late clinical development therapeutic candidates, two of which have completed bioequivalence clinical trials subject to review and approval by the United States Food and Drug Administration and, in some cases, regulatory authorities in other countries. The Company�� six clinical stage therapeutic candidates include RHB-101, RHB-102, RHB-103, RHB-104, RHB-105 and RHB-106.

RHB-101

RHB-101 is a treatment of hypertension, heart failure and left ventricular dysfunction (following myocardial infraction) by means of controlled release of an active ingredient known as carvedilol, which is designed to be administered to patients on a once-daily basis. RHB-101 is based on a patented technology for the controlled release of drugs administered orally.

RHB-102

RHB-102 is a once-daily controlled release oral formulation of ondansetron. RHB-102 utilizes a technology called CDT that uses salts to provide a controlled release of ondansetron.

RHB-103

RHB-103 is an oral thin film formulation of rizatriptan intended for the treatment of acute migraine headaches. Migraine is a neurovascular disorder (related to nerves and blood vessels) characterized by recurrent headaches in one side or both sides of the head.

The product is based on a technology called VersaFilm.

RHB-104

RHB-104 is an antibiotic combination therapy for the treatment of Crohn's disease (with a PIII clinical study underway), as well as Multiple Sclerosis (with an ongoing PIIa clinical study) and Rheumatoid Arthritis. RHB-104 is a combination of clarithromycin, clofazimine and rifabutin, three generic antibiotic ingredients, in a single capsule.

RHB-105

RHB-105, an antibiotics and proton pump inhibitor drug targeting Helico! bacter Pylori infection. RHB-105 is a combination of three approved drug products omeprazole, which is a proton pump inhibitor (the natural body pump that produces the gastric acids used for digesting the food in the stomach), and amoxicillin and rifabutin which are antibiotics. Chronic infection with Helicobacter pylori irritates the mucosal lining of the stomach and small intestine.

RHB-106

RHB-106, is a tablet for the preparation and cleansing of the gastrointestinal tract prior to the performance of abdominal procedures. Its abdominal procedures include diagnostic tests, such as colonoscopy, barium enema or virtual colonoscopy, as well as surgical interventions, such as laparotomy.

The company competes with GlaxoSmithKline, Sanofi-Aventis Groupe, Hoffman-La Roche Ltd, Merck and Co., Inc, Ferring Pharmaceuticals and Salix Pharmaceuticals Inc.

Advisors' Opinion:

• [By Monica Gerson]

  Breaking news

  Vitran Corporation (NASDAQ: VTNC) announced today that it has entered into a definitive arrangement agreement with TransForce pursuant to which TransForce has agreed to acquire all of the outstanding common shares of Vitran not already owned by TransForce for US$6.50 in cash per share, in accordance with TransForce's prior proposal. To read the full news, click here. ReneSola (NYSE: SOL) today announced it signed a Memorandum of Intent (MOI) to sell three utility-scale projects in Western China, with a total capacity of 60MW, to Jiangsu Akcome Solar Science & Technology Co on December 30, 2013. To read the full news, click here. Cooper Tire & Rubber Company (NYSE: CTB) today announced it has terminated the merger agreement with Apollo Tyres (NSE:ApolloTYRE). To read the full news, click here. RedHill Biopharma (NASDAQ: RDHL) today announced that it has entered into a definitive agreement with leading healthcare investor OrbiMed Israel Partners Limited Partnership, an affiliate of OrbiMed Advisors LLC, for the sale of RedHill's American Depository Shares and warrants in a private placement transactionor a total sum of $6.0 million. To read the full news, click here.

  Posted-In: Guggenheim US Stock FuturesNews Eurozone Futures Global Pre-Market Outlook Markets

Best Biotech Companies To Watch For 2014: International Stem Cell Corp (ISCO)

International Stem Cell Corporation, incorporated on June 7, 2005 is a developmental-stage biotechnology company. The Company focused on therapeutic and biomedical product development. The Company�� wholly owned subsidiary Lifeline Cell Technology, LLC (LCT) develops, manufactures and commercializes over 130 human cell culture products, including frozen human primary cells and the reagents (media) needed to grow, maintain and differentiate the cells, in order to address this market opportunity. The Company�� scientists have used a technology called basal medium optimization to systematically produce optimized products designed to culture specific human cell types and to elicit specific cellular behaviors. The Company�� wholly owned subsidiary Lifeline Skin Care, Inc. (LSC) develops, manufactures and markets cosmetic skin care products using an extract derived from its pluripotent stem cells.

Therapeutic Product Candidates

Using the Company's technologies and know-how, the Company is exploring and creating a range of cell types that is useful in therapeutic treatments, which include Liver cells (hepatocytes) that may be used to treat a range of congenital and acquired liver diseases. Neuronal cells for potential treatment of Parkinson's disease and other central nervous system disorders, such as traumatic brain injury, stroke and Alzheimer�� disease. Three-dimensional eye structures to treat degenerative retinal diseases, corneal blindness, and to accelerate corneal healing.

Skin Care Products

The Company�� research scientists developed two skin care products, Defensive Day Serum and Recovery Night Serum, using an extract derived from human parthenogenic stem cells. Defensive Serum contains sunscreen, along with stem cell-derived ingredients. The day serum not only protects the skin from the aging effects of harsh light, but it continues to nurture the skin�� collagen and fibroblasts to give noticeably firmer, smoother, younger-looking ! skin. The Recovery Night Serum is a nighttime therapy that complements the Defensive Day Serum. The night serum nurtures the skin�� collagen and elastin and contains ingredients to defend against damaging free radicals, to help build firmer, smoother, younger and healthier-looking skin.

Research Products

The Company�� Lifeline subsidiary produces and sells over 250 human cell culture products. These products include frozen human cells and stem cells and the reagents needed to grow, maintain and differentiate the cells. These human cell-based products are used domestically and internationally by research scientists in pharmaceutical, academic and government research organizations to study human disease and basic cell biology.

The Company competes with Genzyme Corporation, StemCell, Advanced Cell Technology Inc., Aastrom Biosciences, ViaCyte, Obagi, SkinCeuticals, SkinMedica, Murad, Lonza, Chemicon, Life Technologies, StemCell Technologies, Merck, BioTime and Specialty Media.

Advisors' Opinion:

• [By John Udovich]

  Stem cells may not be in the news much�as the sector has moved beyond the use of embryotic�ones, but small cap stem cell stocks Cellular Dynamics International Inc (NASDAQ: ICEL), International Stem Cell Corp (OTCMKTS: ISCO) and BioRestorative Therapies (OTCBB: BRTX) have been fairly active over the past several trading days as ICEL went public, ISCO raised additional funding and BRTX grabbed more attention:

• [By John Udovich]

  Summer and the slow news for the market that usually comes with it�is over with and both stem cell researchers or small� cap stem cell stocks like Advanced Cell Technology, Inc (OTCBB: ACTC), Neuralstem, Inc (NYSEMKT: CUR), NeoStem Inc (NASDAQ: NBS), International Stem Cell Corp (OTCMKTS: ISCO)�and BioRestorative Therapies (OTCBB: BRTX) having news for investors and traders alike. Consider the following:

• [By John Udovich]

  The results of a recent Pew Center Poll regarding attitudes towards abortion and various forms of stem cell research could be a good sign for the stem cell industry along with small cap stem cell stocks like StemCells Inc (NASDAQ: STEM), NeoStem Inc (NASDAQ: NBS), Neuralstem, Inc (NYSEMKT: CUR),�International Stem Cell Corp (OTCMKTS: ISCO) and BioRestorative Therapies (OTCBB: BRTX). Basically, Americans think that having an abortion is a moral issue with 49% of American adults believing abortion is morally wrong, 23%�view it not as a moral issue and and 15% view it as morally acceptable. However and when Americans were asked about issues surrounding�human embryos, such as stem cell research or in vitro fertilization, as a matter of morality, their views were different.

• [By John Udovich]

  From stem cell burgers to earnings reports, the stem cell industry and small cap players in it like NeoStem Inc (NASDAQ: NBS), International Stem Cell Corp (OTCMKTS: ISCO) and BioRestorative Therapies (OTCBB: BRTX) have been producing some news lately that has probably been overlooked by investors and traders alike given its August. Nevertheless, you might want to pay attention to the following stem cell news:

Best Biotech Companies To Watch For 2014: Incyte Corporation(INCY)

Incyte Corporation focuses on the discovery and development of proprietary small molecule drugs for hematologic and oncology indications, and inflammatory and autoimmune diseases. Its product pipe line includes INCB18424, which is in Phase III clinical trial for myelofibrosis; Phase III trial for polycythemia vera; Phase III trial for essential thrombocythemia; Phase I/II trial to treat solid tumors/other hematologic malignancies; and Phase IIb trail for the treatment of psoriasis. The company?s portfolio also includes INCB28050, a Phase IIb clinical trial product for rheumatoid arthritis; INCB28060, a Phase I/II product for solid tumors; INCB7839, a Phase II product for breast cancer; and INCB24360, a Phase I/II product for solid tumors. It has a collaborative research and license agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; and Pfizer Inc. The company was founded in 1991 and is headquartered in Wilmington, Delaware.

Advisors' Opinion:

• [By John McCamant]

  Incyte's (INCY) crackerjack medicinal chemistry team continues to show that they can create better and differentiated drug candidates from the competition.

  The key near-term driver for INCY is Jakafi growth, and with the increased sales guidance, the company is delivering. The drug's overall profile continues to improve and the recent survival data proves that Jakafi does much more for myelofibrosis patients than just control symptoms.

• [By Maxx Chatsko]

  Pfizer will turn its immediate focus to Xeljanz, a novel JAK3 inhibitor, as it awaits phase 3 data from ertugliflozin several years from now. The drug class has swept the pharmaceutical industry by storm. Novartis (NYSE: NVS  ) and Eli Lilly are developing JAK1 and JAK2 inhibitors for several applications with Incyte (NASDAQ: INCY  ) , while a handful of other companies have molecules of their own. While companies have high hopes for the cancer-fighting potential of JAK inhibitors, such as Jakafi from Novartis and Incyte, the biggest opportunities may lie in the immunology market.

• [By Ben Levisohn]

  Somaiya and team named Gilead and�Neurocrine Biosciences (NBIX) their top picks, hile putting Buy ratings on Celgene, Biogen Idec, Alexion (ALXN), Incyte (INCY), Pharmacyclics (PCYC) and Synageva (GEVA). BioMarin (BMRN), Infinity Pharmaceuticals (INFI) and Amgen (AMGN) earned Neutral ratings.

• [By Maxx Chatsko]

  The best part about being a buy-and-hold investor is that when volatility strikes and analysts and pundits are panicking, you can calmly go about your business and steal great companies at bargain prices. One of the stocks on my top watchlist is Incyte (NASDAQ: INCY  ) , which is a growing biotech company focused on developing oncology and anti-inflammatory drugs. The company's shares have recently fallen below $20 for the first time since early February, which I think warrants a deeper look. In the following video, I'll break down the pros and cons of adding Incyte to your portfolio, although I think the company has a lot of potential in its pipeline.

Best Biotech Companies To Watch For 2014: Biota Pharmaceuticals Inc (BOTA)

Biota Pharmaceuticals, Inc., formerly Nabi Biopharmaceuticals, incorporated on March 14, 1969, is an anti-infective drug development company, with key expertise in respiratory diseases, particularly influenza. Biota developed the neuraminidase inhibitor, zanamivir, subsequently marketed by GlaxoSmithKline as Relenza. The Company�� researches include a series of candidate drugs aimed at treatment of respiratory syncytial virus (RSV) disease and Hepatitis C (HCV) virus infections. In addition, Biota and Daiichi Sankyo co-own a range of second generation influenza anti-virals, of which the lead product lnavir, is approved for marketing in Japan.

The Company�� products include Zanamivir, Inavi, Phoslyra, BioStar OIA FLU and BioStar OIA FLU A/B. Zanamivir is a neuraminidase inhibitor for the treatment and prophylaxis of influenza marketed as Relenza by GlaxoSmithKline. Inavi (laninamivir) is a neuraminidase inhibitor marketed by Daiichi Sankyo in Japan. Phoslyra is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (ESRD). BioStar OIA FLU and BioStar OIA FLU A/B are influenza diagnostic tests, which are marketed by Inverness Medical as part of their BioStar product range.

Relenza is delivered directly to the primary site of infection on the lungs, using a Disk Inhaler device. Relenza is approved in over 50 countries for the treatment of influenza, including in the United States, the European Union, Japan and Australia. Relenza is also approved for use as a preventative (prophylactic) treatment against influenza. Inavir is approved for sale in Japan for the treatment of influenza in adults and children. Daiichi Sankyo has applied to sell Inavir in Japan for the prevention of influenza.

PhosLo and Phoslyra are different dose forms of calcium acetate; a phosphate binder approved in multiple countries for the control of hyperphosphatemia (high serum phosphate) in patients with end stage renal disease (ESRD). PhosLo and Pho! slyra were sold to Fresnius Medical Care. Biota, together with its Japanese based partner, Daiichi Sankyo, have developed an inhaled antiviral compounds for influenza, called long acting inhaled neuraminidase inhibitors (LANI). Biota's human rhinovirus (HRV) drug for the prevention and treatment of the causes of the common cold, BTA798, has completed Phase I, Phase IIa and Phase IIb clinical trials.

Advisors' Opinion:

• [By gurujx]

  Biota Pharmaceuticals Inc (BOTA) Reached the 3-year Low of $2.42

  The prices of Biota Pharmaceuticals Inc (BOTA) shares have declined to close to the 3-year low of $2.42, which is 93.3% off the 3-year high of $34.92.

Best Biotech Companies To Watch For 2014: Cytomedix Inc (CMXI)

Cytomedix, Inc. (Cytomedix), incorporated in April 29, 1998, is a regenerative therapies company marketing and developing products within the United States and internationally .The Company commercializes cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. The Company is a commercial operation, and a robust clinical pipeline representing a logical extension of its commercial technologies in the evolving field of regenerative medicine. Cytomedix primarily operates in the United States. Its commercial offerings are centered on its point of care platform technologies for the safe and efficient separation of blood and bone marrow to produce platelet based therapies or cell concentrates.

The Company markets and selsl two distinct platelet rich plasma (PRP) technologies, the AutoloGel System for wound care and the Angel concentrated Platelet Rich Plasma (cPRP) Sytem in orthopedic and cardiovascular markets. Its clinical pipeline includes the ALDH, which are cell-based therapies (Bright Cells). In February 2012, the Company acquired Aldagen, Inc.

The AutoloGel System

The AutoloGel System is a point of care device for the production of a platelet based bioactive therapy derived from a small sample of the patient�� own blood. Using the patient�� own platelets as a therapeutic agent, AutoloGel harnesses the body�� natural healing processes to deliver growth factors, chemokines and cytokines known to promote angiogenesis and to regulate cell growth and the formation of new tissue.

Angel Product Line

The Angel concentrated Platelet Rich Plasma (cPRP) System is a multi-functional cell separation device which produces concentrated platelet rich plasma for use in the operating room and clinic and is used in a range of orthopedic and cardiovascular indications. Similar to the AutoloGel System, the Angel System is a point of care device for the production of a concentrated, aseptic platelet! -based bioactive therapy derived from a small sample of the patient�� own blood. The resulting cPRP is applied at the site of injury to promote healing. The Angel product line also includes ancillary products such as phlebotomy and applicator supplies and activAT. activAT is designed to produce autologous thrombin serum from platelet poor plasma and is sold exclusively in Europe and Canada, where it provides a safe alternative to bovine-derived products.

ALDHbr Cell Technology and Development Pipeline

The ALDHbr (Bright Cell) technology is an approach to cell-based regenerative medicine and a logical extension of its commercial technologies in the evolving regenerative medicine market, with potential clinical indications in markets with unmet medical needs such as peripheral arterial disease and ischemic stroke. The Bright Cell technology is in that it utilizes an intracellular enzyme marker to facilitate fractionation of essential regenerative cells from a patient�� bone marrow. The bone marrow fractionation process identifies and isolates active stem and progenitor cells expressing high levels of the enzyme aldehyde dehydrogenase, or ALDH, which is a key enzyme involved in the regulation of gene activities associated with cell proliferation and differentiation.

The Company�� lead product candidate, ALD-401, is an autologous preparation of Bright Cells for the post-acute treatment of ischemic stroke. ALD-401 is being evaluated in the RECOVER-Stroke clinical study, an ongoing 100-patient, double-blind, placebo-controlled Phase 2 study in patients with unilateral, cerebral ischemic stroke with an NIH stroke scale score of less than 22. An additional product candidate, ALD-301, is in clinical development for peripheral arterial disease (PAD), a condition causing reduced flow of blood and oxygen to muscles in the leg. It has completed a Phase 1/2 study of autologous ALD-301 in critical limb ischemia (CLI), a late stage condition caused by PAD. The Phase 2 PACE! (Patient! s with Intermittent Claudication Injected with ALDH Bright Cells) study is an 80 patient, double-blind, placebo-controlled clinical trial intended to demonstrate the safety and efficacy of ALD-301 (Bright Cells) in patients diagnosed with IC.

The Company competes with Harvest Technologies (a subsidiary of Terumo), Biomet, Arteriocyte, and Arthrex.

Advisors' Opinion:

• [By Bryan Murphy]

  When traders think of post-surgical wound management stocks, they may first think of names like Cytomedix, Inc. (OTCBB:CMXI) or Alliqua Inc. (OTCMKTS:ALQA). And well they should. Both companies have something of a history in the arena. ALQA is the purveyor of SilverSeal and Hydress antibiotic bandages, while CMXI is the developer of the AutoloGel system, which induces an affected patient's on body to do what it's supposed to do if there's a wound that won't heal. Cytomedix also makes the Angel platelet-rich plasma (PRP) delivery system. There's a relatively new name to add to the list of game-changing stocks in wound-management industry, however.... Arch Therapeutics Inc. (OTCBB:ARTH). The company is developing - well, has developed - a product called AC5 that nips post-surgical bleeding in the bud, largely negating the need for other post-surgical bleeding-control measures.

Best Biotech Companies To Watch For 2014: Protalix Biotherapeutics Inc (PLX)

Protalix BioTherapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx protein expression system, ProCellEx. Using its ProCellEx system, the Company is developing a pipeline of biosimilar or generic versions of recombinant therapeutic proteins based on its plant cell-based expression technology, which focuses pharmaceutical markets and that rely upon known biological mechanisms of action. ProCellEx protein expression system consists of a set of technologies and capabilities for the development of recombinant proteins, including advanced genetic engineering technology and plant cell-based protein expression methods. Its ProCellEx protein expression system is built on flexible custom-designed bioreactors made of polyethylene and optimized for the development of complex proteins in plant cell cultures. In June 2010, it had completed the preliminary phase I clinical trial of PRX-105.

Taliglucerase Alfa

Taliglucerase alfa is a plant cell expressed recombinant glucocerebrosidase enzyme (GCD) for the treatment of Gaucher disease. The Company has commenced pre-clinical studies of an oral form of taliglucerase alfa. Its oral taliglucerase alfa is a plant cell expressed form of GCD that is naturally encapsulated within carrot cells genetically engineered to express the GCD enzyme. Pre-clinical studies of oral taliglucerase alfa demonstrate the stability of the enzyme in the cell and the capacity of the cell�� cellulose wall to protect the enzyme against degradation in the digestive tract in an in-vitro model of the stomach and intestines. Additionally, rats fed with lyophilized carrot cells expressing GCD have accumulated the active enzyme in the target organs; the spleen and liver. As of December 31, 2010, the Company had completed Phase III Clinical Trial.

PRX-102

The Company is developing PRX-102, its plant cell expressed modified version of the recombinant ! alpha-GAL-A protein, a therapeutic enzyme for the treatment of Fabry disease. Fabry disease is a rare, hereditary, genetic lysosomal storage disorder in humans caused by an X-lined deficiency of the alpha-GAL-A enzyme. The Company is in the animal evaluation testing phase of the development of PRX-102, which tests are based on a mouse model for Fabry disease.

Acetylcholinesterase

Protalix Ltd. is a wholly owned subsidiary of the Company is licensed the rights to certain technology under a research and license agreement with Yissum Research and Development Company (Yissum) and the Boyce Thompson Institute, Inc. Pursuant to the agreement, the Company is developing PRX-105, a plant cell-based acetylcholinesterase (AChE) and its molecular variants for the use in several therapeutic and prophylactic indications, as well as in a biodefense program and an organophosphate-based pesticide treatment program.

As of December 31, 2010, its in-vitro experiments of PRX-105 have shown that the acetylcholinesterase enzyme in its ProCellEx protein expression system demonstrates biological activity on biochemical and cellular levels. In addition, early animal studies demonstrated that the acetylcholinesterase expressed in its ProCellEx protein expression system was able to treat animals exposed to the nerve gas agent analogues, both when injected with its acetylcholinesterase product candidate immediately before exposure or when injected after exposure. In March 2010, it initiated a preliminary phase I clinical trial of PRX-105, which the Company completed in June 2010.

pr-antiTNF

pr-antiTNF is a candidate for the treatment of certain autoimmune diseases such as rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing, spondylitis, psoriatic arthritis and plaque psoriasis. The Company has designed the antiTNF as pr-antiTNF. pr-antiTNF is a plant cell-expressed recombinant fusion protein made from the soluble form of the human TNF receptor (TNFR), f! used to t! he Fc component of a human antibody domain. pr-antiTNF has an identical amino acid sequence to Enbrel and its in-vitro and preclinical animal studies have demonstrated that pr-antiTNF exhibits similar activity to Enbrel. Specifically, pr-antiTNF binds TNF thereby inhibiting it from binding to cellular surface TNF receptors and protects L929 cells from TNF-induced apoptosis in a dose-dependent manner.

The Company competes with Genzyme, Actelion, Crucell N.V., Biolex, Inc., Chlorogen, Inc., Greenovation Biotech GmbH, Symbiosys, Novartis AG/Sandoz Pharmaceuticals, BioGeneriX AG, Stada Arzneimittel AG, BioPartners GmbH and Teva.

Advisors' Opinion:

• [By Maxx Chatsko]

  Industrial biotech isn't the only industry headed to Brazil. Protalix (NYSEMKT: PLX  ) entered into a technology transfer agreement with Brazil's Ministry of Health last week that will pay the company $280 million. The deal is big news for Protalix's first product, Elelyso/Uplyso, which was developed with partner Pfizer (NYSE: PFE  ) . The treatment is approved as an enzyme replacement therapy, or ERT, for adults with type 1 Gaucher disease, and it marks a huge step forward for the future of biomanufacturing. In the following video, Fool contributor Maxx Chatsko explains what this means for the product's commercialization and the adoption of Protalix's novel plant cell-based expression system for therapeutic proteins.

• [By Keith Speights]

  Other investors might wish that Pfizer would use some of its cash to acquire a few smaller companies. Protalix BioTherapeutics (NYSEMKT: PLX  ) has been mentioned as one possible candidate. The two companies already partner together on Gaucher disease drug Elelyso. In February, Protalix spurred rumors that Pfizer could be interested in buying the company after it announced that it had engaged Citigroup to pursue a "broad array of strategic alternatives."

Best Defense Stocks To Invest In Right Now

Popular Posts: 6 Biotechnology Stocks to Buy Now5 Oil and Gas Stocks to Buy Now9 Biotechnology Stocks to Sell Now Recent Posts: 3 Aerospace and Defense Stocks to Buy Now 4 Mortgage Stocks to Buy Now 5 Diversified Utilities Stocks to Buy Now View All Posts

This week, four Mortgage stocks are improving their overall rating on Portfolio Grader. Each of these rates an “A” (“strong buy”) or “B” overall (“buy”).

This week, New Hampshire Thrift Bancshares, Inc. (NASDAQ:) is showing significant improvement as the company’s rating hops from a C (“hold”) to a B (“buy”). New Hampshire Thrift Bancshares is a holding company for Lake Sunapee Bank, which is a provider of banking and other financial services in New Hampshire and Vermont. .

Top Prefered Companies To Own For 2015: Lockheed Martin Corporation(LMT)

Lockheed Martin Corporation engages in the research, design, development, manufacture, integration, operation, and sustainment of advanced technology systems and products in the areas of defense, space, intelligence, homeland security, and government information technology in the United States and internationally. It also provides management, engineering, technical, scientific, logistic, and information services. The company operates in four segments: Aeronautics, Electronic Systems, Information Systems & Global Services (IS&GS), and Space Systems. The Aeronautics segment offers military aircraft, including combat and air mobility aircraft, unmanned air vehicles, and related technologies. Its products and programs comprise the F-35 multi-role, stealth fighter; the F-22 air dominance and multi-mission stealth fighter; the F-16 multi-role fighter; the C-130J tactical transport aircraft; and the C-5M strategic airlifter modernization program; and support for the P-3 maritime patrol aircraft, and the U-2 high-altitude reconnaissance aircraft. The Electronic Systems segment provides air and missile defense; tactical missiles; weapon fire control systems; surface ship and submarine combat systems; anti-submarine and undersea warfare systems; land, sea-based, and airborne radars; surveillance and reconnaissance systems; simulation and training systems; and integrated logistics and sustainment services. The IS&GS segment offers information technology solutions and advanced technology primarily in the areas of software and systems integration for space, air, and ground systems to various defense and civil government agencies. The Space Systems segment provides government and commercial satellites; strategic and defensive missile systems, including missile defense technologies and systems, and fleet ballistic missiles; and space transportation systems. Lockheed Martin Corporation was founded in 1909 and is based in Bethesda, Maryland.

Advisors' Opinion:

• [By Jose Pagliery]

  The NGI system, which started as a pilot program in 2009, was designed by defense contractor Lockheed Martin (LMT) in a deal worth up to $1 billion. The facial recognition software was built by MorphoTrust, a Billerica, Massachusetts-based company that already does the biometric scans at 450 U.S. airports and DMVs in 42 states.

• [By Victor Selva]

  The company has a current ratio of 16.25% which is higher than the one registered by Embraer S.A. (ERJ) and Wesco Aircraft Holdings Inc (WAIR), but lower than Huntington Ingalls Industries, Northrop Grumman Corp (NOC) and Boeing Co (BA). But for investors looking for a higher ROE, Lockheed Martin Corporation (LMT) could be the option.

• [By Rich Smith]

  Lockheed Martin (NYSE: LMT  ) landed two contracts in Tuesday's list of new Pentagon spending awards -- one large, one not so much.

  The bigger of Lockheed's two contract wins was actually a modification to an existing contract. Lockheed will receive $101.6 million to pay for "re-phasing" a Spacecraft Integration and Test contract to put it in line with new launch dates for a pair of Defense Meteorological Satellite Program, or DMSP, launches, specifically Flight 19 and Flight 20.

• [By Rich Smith]

  On Monday, the Department of Defense awarded 19 contracts, which added up to just under $1.5 billion in total value. The largest award actually went to a private company to pay for "full line food distribution" in Okinawa. But the second-largest contract went to Lockheed Martin (NYSE: LMT  ) .

Best Defense Stocks To Invest In Right Now: Implant Sciences Corp (IMSC)

Implant Sciences Corporation (Implant Sciences), incorporated in August 31,1984, develops, manufactures and sells sensors and systems for the security, safety and defense (SS&D) industries. Its technologies are used worldwide in security and inspection applications. Implant Sciences has developed technologies used in explosives trace detection (ETD), and and narcotics trace detection (NTD) applications and market and sell handheld ETD and benchtop ETD and NTD systems that use its technologies. The systems are used by private companies and Government agencies to screen baggage, cargo, vehicles, other objects and people for the detection of trace amounts of explosives. Implant Sciences have developed explosives detection systems designed for use in aviation and transportation security, high threat facilities and infrastructure, military installations, customs and border protection, and mail and cargo screening. The systems use the Quantum Sniffer technologies, including photon-based, non-radioactive ion source in combination with ion mobility spectrometry, a detection tool sensitive to the speeds with which ions of various substances move through the air to electronically detect minute quantities of explosives vapor and particles.

Quantum Sniffer QS-H150 Portable Explosives Detector

The Quantum Sniffer QS-H150 Portable Explosives Detector employs a vortex collector for the simultaneous detection of explosives particulates and vapors with or without physical contact and in real-time. The QS-HS150 can detect vapors and nanogram quantities of explosives particulates for explosives substances considered to be threats. The substances include military and commercial explosives, improvised and homemade explosives, and propellants and taggants.

The QS-H150 has automatic and continuous self-calibration. It monitors its environment, senses changes that would affect its accuracy, and re-calibrates accordingly. The system requires no user intervention and no calibration cons! umables. The detection process begins with the collection of a sample with its vortex collector. After collection, the sample is ionized photonically and analyzed using ion mobility spectrometer (IMS) technology. The presence of a threat substance is indicated by a visible and audible alarms. The threat substance is then identified and displayed on the integrated liquid crystal display (LCD) screen. When detecting a threat substance, the QS-H150 rapidly alarms. This real-time detection limits equipment contamination and allows for fast clear-down.

Quantum Sniffer QS-B220 Benchtop Explosives and Narcotics Detector

QS-B220 Benchtop Explosives and Narcotics Detector uses dual IMS with non-radioactive ionization for the detection and identification of a range of military, commercial, and improvised explosives as well as narcotics. The QS-B220 uses a sample trap which is wiped on the surface to be interrogated for explosives or narcotics particles.

The QS-B220 has automatic and continuous self-calibration. It monitors its environment, senses changes that would affect its accuracy, and re-calibrates accordingly.

Quantum Sniffer TM QS-Hx Portable Explosives Detector

The Company is focusing in developing a next-generation handheld detector that will use dual IMS non-radioactive ionization for the detection and identification of a range of military, commercial and improvised explosives, as well as narcotics. The QS-Hx will have automatic and continuous self-calibration, multi-level password-protected data security and will include a data management interface with data export to a network for recordkeeping, providing a link with the central command centers and logistics systems used by carriers.

Miniature Mass Spectrometer

The Company�� acquisition of Ion Metrics enabled it to obtain miniaturized quadrupole mass spectrometry (QMS) detector technology. The QMS detector is roughly the size of an AA battery and has low manufactur! ing costs! . When used in conjunction with an IMS, the QMS detector senses the molecular weight of the chemical species resulting in an orthogonal detection method in which a more fundamental characteristic of a substance is measured. It is developing interfaces for integrating the QMS detector into its future products.

Hyphenated Detectors

Depending on the application and the number of interfering background chemicals, it may be necessary to incorporate additional orthogonal detection methods. The combination of multiple sensors in series is known as employing hyphenated methods. By measuring different properties of the same species, interferents are separated from target species for a deterministic detection and identification and have minimum rates of false alarms. It is developing hyphenated systems employing conventional ion mobility, differential mobility and quadrupole mass spectrometry. As of June 30, 2012, it has one patent issued in real-time trace detection by IMS and QMS and two hyphenated system patents pending.

The Company competes with Morpho Detection, Inc., NucTech Company Limited and Smiths Detection, Inc.

Advisors' Opinion:

• [By James E. Brumley]

  It's not an uncompetitive market. Names like Implant Sciences Corporation (OTCMKTS:IMSC) and NXT-ID (OTCBB:NXTD) are battling in the security and facility-defense arena as well; IMSC makes explosives-detection and drug-detection hardware, while NXTD designs 3D image-rendering software that caters to the unique needs of prison security personnel, though the same technology has been proven in more traditional functions like building-security systems that keep certain people out rather than in. Neither Implant Sciences nor NXT-ID compete directly head-to-head with View Systems, however ... fortunately for them. See, VSYM is considered by some to be the best in the industry.

Best Defense Stocks To Invest In Right Now: Poly Shield Technologies Inc (SHPR)

Poly Shield Technologies Inc. (Poly Shield), incorporated on March 2, 2000, is a research, development and marketing company providing environmental, energy saving and durability solutions. The Company's are designed and manufactured under the advanced bio-scrubber technology and includes a line of protective fluoropolymer coatings. Poly Shield�� fluoropolymer products are manufactured at a production facility in Florida. Poly Shield�� manufactured fluoropolymer coatings are used in a number of different industries including marine, aerospace, oilfield, industrial, commercial, and residential applications. In addition, Poly Shield offers a line of antimicrobial coatings for use in hospital or food industries. In December 2013, Poly Shield Technologies Inc sold New World Technologies Group, Inc. to Viveros.

The Company's products include bio-scrubber, supershield, superiorshield and microshield. Its products are used in aerospace, cruise ship lines, marine, military, oil, and energy production industries. The Company's bio-scrubber is designed to remove alkali metals from fuel in an effort to protect gas turbines from high temperature corrosion. The technology has been installed on active ships within the cruise line industry.

SuperShield is a fluoropolymer coating that is formulated to work with a variety of residential, commercial, industrial and marine applications. It is a fluoroplymer resin that offers weathering ability and the choice of temperature curing. Its flagship product, SuperShield 100, containing fluoropolymer resins provides up to a 50 year service life on a steel and metal surfaces. Its SuperShield S is superhydrophobic and superoleophobic, with characteristic complex micro and nanoscopic surface, which minimizes adhesion. SuperShield S100 is also superhydrophobic and superoleophobic. SuperShield S100 is provides 50 year service life. The ultimate anti-fouling coating for ship hulls, oilfield rigs, heavy equipment, airplanes, bridges, etc.

! SuperiorShield is protective and energy saving roof coatings. Its superiorShield coating reduces heat transfer through infrared radiation, conduction and convection. SuperiorShield has the capability to reflect 90% of the suns ultraviolet (UV) rays.

MicroShield is a anti-microbial coating. MicroShield is an active antibacterial destroying the cell membrane and inducing oxidative deoxyribonucleic acid (DNA) and protein damage of microbes. It also acts as a bacteriostat, virostat and fungistat, inhibiting bacterial, viral and fungal growth.

Advisors' Opinion:

• [By Peter Graham]

  Small cap stocks Soul and Vibe Interactive Inc (OTCBB: SOUL), Globalstar, Inc (OTCMKTS: GSAT) and Poly Shield Technologies Inc (OTCBB: SHPR) have been getting some attention lately in various investment newsletters or investor alerts with at least two of these stocks being the subject of some sort of paid stock promotional or investor relations type of activities. With that in mind, just how hot are these three small cap stocks for investors or traders? Here is a quick reality check:

Best Defense Stocks To Invest In Right Now: Rolls-Royce Holdings PLC (RYCEY)

Rolls-Royce Holdings plc, formerly Rolls-Royce Group plc is a provider of power systems and services for use on land, at sea and in the air. The Company operates in four segments: civil aerospace, defense aerospace, marine and energy. The civil aerospace is engaged in development, manufacture, marketing and sales of commercial aero engines and aftermarket services. The defense aerospace is engaged in development, manufacture, marketing and sales of military aero engines and aftermarket services. The marine segment is engaged in development, manufacture, marketing and sales of marine propulsion systems and aftermarket services. The energy segment is engaged in development, manufacture, marketing and sales of power systems for the offshore oil and gas industry and electrical power generation and aftermarket services. In January 2013, the Company bought PKMJ Technical Services. In January 2013, Alstom SA acquired Tidal Generation Limited from the Company.

During the year ended December 31, 2010, it acquired ODIM ASA. In June 2011, Daimler AG and Rolls-Royce Holdings PLC had secured around 94% interest in Tognum AG-DJ. In September 2011, the Company acquired R Brooks Associates.

Civil aerospace

The Company�� civil aerospace business provides the powers for 30 different types of commercial aircraft in a range of markets, such as widebody, narrowbody, corporate and regional aircraft. As of December 31, 2010, it had over 13,000 engines in service with 650 airlines, freight operators and lessors and 4,000 corporate operators. Its civil aerospace products include large aircraft engines, small aircraft engines and helicopter engines. The Company�� Trent 700 is an engine on the Airbus A330. The Trent 1000 is powering the Boeing 787 on the aircraft�� flight test schedule. It provides a range of services, such as TotalCare, CorporateCare, helicopters services, financial services, training and technical publications.

Defence Aerospace

The Compan! y is a provider of defence aero-engine products and services, with 18,000 engines in service for 160 customers in 103 countries. It is also the supplier of engines for transport aircraft globally, powering fleets, such as the C-130, C-130J, Spartan C-27 and Osprey V-22. It is also involved in research projects, such as Adoptive Versatile Engine Technology (ADVENT), which is designed to reduce fuel consumption. Its engines power aircraft in all sectors, such as transport, combat, reconnaissance, training, helicopters and unmanned aerial vehicles. The defense aerospace segment of the Company provides engines power aircraft in all sectors, such as transport, combat, reconnaissance, training, helicopters and unmanned aerial vehicles. Its products include combat jets, helicopters, transporters, trainers, tactical aircraft, unmanned aerial vehicles and distributed generation systems. It provides a range of services, such as training, technical publications and service locations.

Marine

The Company focuses on power, propulsion and motion control solutions and serves over 2,500 customers and has equipment installed on 30,000 vessels operating worldwide. As of December 31, 2010, the Company had 650 designed and equipped vessels operating in the offshore oil and gas sector. As of December 31, 2010, it had more than 2,500 marine customers and has equipment installed on over 30,000 vessels worldwide, including those of 70 navies. The energy business supplies gas turbines, compressors and diesel power units. Its products include automation and control, bearings and seals, deck machinery, electrical power systems, engines, gears, propulsors, ship design, shiplifts and submarine equipment. It provides a range of services, such as global support network, spares and tools, field shop services, technical support, training, tailored solutions and upgrading.

Energy

The Company is a provider of gas turbines for onshore and offshore applications. The Company�� energy busi! ness is e! ngaged in two activities: supply power to the oil and gas sector, and the provision of power generation products and services. Its products include gas engines, gas turbine engines, gas compression, diesel engines, fuel cells, and automation and control systems. Its services consist of long term service agreements, component supply and technical support, distributed generation systems and training. During the year ended December 31, 2010, it conducted a range of a tidal power turbine, anchored on the sea bed off the coast of Scotland. During 2010, this had generated 500 kilo-watt at full power and has been successfully linked into the national grid.

Advisors' Opinion:

• [By Rich Smith]

  The Department of Defense awarded a round dozen defense contracts Friday, worth just under $7.2 billion in aggregate. The bulk of the contracts -- $7 billion worth -- were split among eight small privately held firms scattered around New Jersey, Maryland, Indiana, and Virginia contracted to supply software and systems engineering services in support of the Army's Software Engineering Center. But a handful of better-known -- and, more importantly to investors, publicly traded -- companies won contracts as well. Namely:

• [By Rich Smith]

  According to the DSCA, Lockheed Martin (NYSE: LMT  ) will be the prime contractor on this sale, which is valued at $588 million. It would involve not only the sale of the planes per se, but also eight Rolls Royce (NASDAQOTH: RYCEY  ) AE 2100D3 engines for the four-engine planes, and two spare engines, plus modifications to be made on the planes, radio equipment and other accessories, technical documentation, three years of training, and related logistics services.

Best Supermarket Companies For 2014

LONDON -- Ace City investor�Neil Woodford�has thrashed the FTSE 100 over the last five, 10, and 15 years. Hence, I always keep an eye on his holdings for promising investment ideas.

Woodford is�very�selective in picking shares for his 20 billion pound funds. Fewer than one in five of the U.K.'s top 100 companies earn a place in his market-beating portfolios.

The following three companies have notable records as fast dividend growers over the last four years:

Company

Share Price (pence)

Annual Dividend Growth (%)

Forecast Yield (%)

Smith & Nephew� (LSE: SN  )

753

20

2.3

Wm. Morrison Supermarkets� (LSE: MRW  )

266

20

4.9

5 Best Gas Stocks To Buy Right Now: Knightsbridge Tankers Limited(VLCCF)

Knightsbridge Tankers Limited, through its subsidiaries, engages in the seaborne transportation of crude oil and dry bulk cargoes worldwide. The company?s customers include oil companies, tanker companies, dry bulk companies, petroleum products traders, government agencies, and other entities. As of September 6, 2011, it owned and operated a fleet of four double-hull very large crude carriers, and four Capesize dry bulk carriers. The company was founded in 1996 and is based in Hamilton, Bermuda.

Advisors' Opinion:

• [By Maxx Chatsko]

  The horrendous flops
  I wrote a blog post explaining why Knightsbridge Tankers (NASDAQ: VLCCF  ) made the right move in slashing its dividend and why its prospects were looking up. The shipping company was extremely undervalued at the time, so why was I wrong? I made the mistake of thinking that a company trading below book value represented good value for shareholders. In reality, many shipping companies were -- and are -- trading below shareholders' equity because their fleets are enormously valuable assets. Unfortunately, that inflates book value enormously. It may not seem so harmful at first, but perpetually low charter rates have actually forced many shippers -- including Knightsbridge -- to sell tankers at less than market value to keep the lights on. Those practices can erase large chunks of book value overnight.

Best Supermarket Companies For 2014: Ironwood Pharmaceuticals Inc.(IRWD)

Ironwood Pharmaceuticals, Inc. discovers, develops, and commercializes medicines targeting therapeutic needs. The company is developing Linaclotide, a first-in-class compound that is in Phase III clinical trials for the treatment of irritable bowel syndrome with constipation, chronic constipation, and other lower gastrointestinal conditions. It also focuses on the research and development of early stage product candidates and preclinical research in various therapeutic areas, including gastrointestinal disease, pain and inflammation, respiratory disease, and cardiovascular disease. The company has a collaboration agreement with Forest Laboratories, Inc. to jointly develop and commercialize linaclotide in North America; a license agreement with Almirall, S.A. to develop and commercialize linaclotide in Europe; and a license agreement with Astellas Pharma Inc. that provides Astellas Pharma with the right to develop and commercialize linaclotide in Japan, South Korea, Taiwan, Thailand, the Philippines, and Indonesia. It serves patients, payors, and healthcare providers. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Cambridge, Massachusetts.

Advisors' Opinion:

• [By Lee Jackson]

  While very upbeat on the sector as a whole, UBS was very cautious on sell-rated Ironwood Pharmaceuticals, Inc (NASDAQ: IRWD) and ImmunoGen Inc. (NASDAQ: IMGN). Neutral-rated Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) and Seattle Genetics Inc. (NASDAQ: SGEN) were also viewed with a skeptical eye.

Best Supermarket Companies For 2014: CES Synergies Inc (CESX)

CES Synergies, Inc., formerly Green Living Concepts Inc., incorporated on April 26, 2010, is a development-stage company. The Company is a consulting firm specializing in construction and renovation. The Company operates in three segments: remediation, demolition and insulation. Remediation derives its income from mold remediation and abatement services for a range of environments. Demolition offers a scale commercial demolition and wrecking down to interior and selective demolition and strip down services. The Company�� third segment, Insulation, derives its revenue from re-insulation and insulation of new and remodeling projects.

On November 1, 2013, the Company entered into and closed an agreement and plan of merger with CES Acquisitions, Inc., a wholly owned subsidiary of the Company (the Subsidiary) and Cross Environmental Services, Inc. (CES). Pursuant to the merger agreement, the Subsidiary merged into CES, such that CES became a wholly owned subsidiary of the Company and business of CES became the business of the Company. CES is an asbestos abatement, demolition, and mold remediation services company.

Advisors' Opinion:

• [By James E. Brumley]

  Most of the time, investors can figure out where the better investment opportunities are. Take the growth of heavy construction (commercial, manufacturing, energy production, institutional, etc) as an example. To capture the post-recession rebound in that segment of the construction market, most people have turned to names like Chicago Bridge & Iron Company N.V. (NYSE:CBI) and Jacobs Engineering Group Inc. (NYSE:JEC), both of which take on major construction projects. Big construction companies like Jacobs Engineering Group and Chicago Bridge & Iron Company aren't the only ways to play the recovery of the industry, though. Investors interested in looking one step beyond the obvious possibilities will find that a company like CES Synergies Inc. (OTCBB:CESX) is actually the better opportunity.

• [By John Udovich]

  Small cap�stocks Vertex Energy Inc (NASDAQ: VTNR), Industrial Services of America, Inc (NASDAQ: IDSA) and�up and coming CES Synergies Inc (OTCBB: CESX) who are focused on providing environmental, waste removal, recycling or remediation services have been real outperformers this year. In fact, Nasdaq listed Vertex Energy Inc is up 70.7% and Industrial Services of America, Inc is up 57.7% while�OTC listed CES Synergies Inc is up 76.5%. Here is a closer look at these small cap environmental services�stocks, their performance�and what they are doing right:

Best Supermarket Companies For 2014: Alimera Sciences Inc.(ALIM)

Alimera Sciences, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. The company focuses on diseases affecting the back of the eye or retina. The company is developing ILUVIEN, an intravitreal insert in phase-3 clinical trials for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN insert designed to be inserted into the patient?s eye to release a daily dose of fluocinolone acetonide over an anticipated period of 24 to 36 months. The company also conducts phase-2 clinical trials on ILUVIEN for the treatment of the dry form of age-related macular degeneration (AMD), the wet form of AMD, and retinal vein occlusion. In addition, it conducts testing on two classes of nicotinamide adenine dinucleotide phosphate oxidase inhibitors. Further, the company develops I LUVIEN inserter, a custom insertion system for ILUVIEN. Alimera Sciences, Inc. was founded in 2003 and is headquartered in Alpharetta, Georgia.

Advisors' Opinion:

• [By Smith On Stocks]

  This note focuses on the implications of the complete response letter (CRL) received by Alimera (ALIM) for Iluvien. This product was developed by pSivida (PSDV) but was partnered with Alimera. This report deals only with the investment significance for pSivida.

Best Supermarket Companies For 2014: Genworth Financial Inc (GNW)

Genworth Financial, Inc., a financial security company, provides insurance, wealth management, investment, and financial solutions in the United States and internationally. The company offers various insurance and fixed annuity products, including life and long-term care insurance products; payment protection insurance products for consumers primarily to meet specified payment obligations; and wealth management products, such as managed account programs with advisor support and financial planning services. It also provides mortgage insurance products and related services to insure prime-based, individually underwritten residential mortgage loans or flow mortgage insurance; and mortgage insurance on a structured or bulk basis, as well as offers services, analytical tools, and technology that enable lenders to operate and manage risk. In addition, the company provides institutional products consisting of funding agreements, funding agreements backing notes, and guaranteed in vestment contracts. Genworth Financial, Inc. distributes its products and services through financial intermediaries, advisors, independent distributors, affinity groups, and sales specialists. The company was founded in 2003 and is headquartered in Richmond, Virginia.

Advisors' Opinion:

• [By Eric Volkman]

  Genworth Financial (NYSE: GNW  ) plans to to eliminate roughly 400 positions, which includes 150 open jobs that it will not fill, the company announced Thursday.

Best Supermarket Companies For 2014: Alliance Holdings GP L.P.(AHGP)

Alliance Holdings GP, L.P., through its subsidiaries, produces and markets coal primarily to utilities and industrial users in the United States. It produces a range of steam coal with varying sulfur and heat contents. The company operates nine underground mining complexes in Illinois, Indiana, Kentucky, Maryland, and West Virginia. As of December 31, 2010, it had approximately 697.4 million tons of proven and probable coal reserves in Illinois, Indiana, Kentucky, Maryland, Pennsylvania, and West Virginia. In addition, the company leases land; and operates a coal loading terminal, with a capacity of 8.0 million tons with ground storage of approximately 60,000 to 70,000 tons, on the Ohio River at Mt. Vernon, Indiana. Further, it engages in purchasing and selling coal; and providing services, including ash and scrubber sludge removal, coal yard maintenance, and arranging alternate transportation services. Alliance GP, LLC, serves as the general partner of the company. Allian ce Holdings GP, L.P. is based in Tulsa, Oklahoma.

Advisors' Opinion:

• [By Seth Jayson]

  Calling all cash flows
  When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Alliance Holdings GP (Nasdaq: AHGP  ) , whose recent revenue and earnings are plotted below.

• [By Robert Rapier]

  The National Association of Publicly Traded Partnerships (NAPTP) lists five MLPs in the category ��atural Resources – Coal,��although two of the five are Alliance Holdings (NYSE: AHGP) and its operating affiliate, Alliance Resource Partners (NYSE: ARLP). The other three are Natural Resource Partners (NYSE: NRP), Rhino Resource Partners (NYSE: RNO), and Oxford Resource Partners (NYSE: OXF).

Best Prefered Stocks To Invest In Right Now

We first wrote about James River Coal (JRCC) in mid-April and assessed its chances of bankruptcy based on conditions at that point. The conclusion was that James River Coal's future was mostly dependent on the price of metallurgical coal. A moderate to strong recovery in metallurgical coal prices would likely make the shares worth several times the $1.53 per share price that it traded at then. However, if the price of metallurgical coal remained flat, then James River Coal would face significant bankruptcy risk in 2014.

Developments in metallurgical coal pricing since that article have increased James River Coal's bankruptcy risk, although management appears to be doing an excellent job in minimizing expenditures. If the metallurgical coal market continues to struggle for much longer, cost management will not be enough, and it will be necessary to seek out additional funding, which could be extremely challenging for James River Coal to secure.

Top 10 High Dividend Companies To Watch For 2015: Plains Exploration & Production Company(PXP)

Plains Exploration & Production Company, an independent oil and gas company, primarily engages in acquiring, developing, exploring, and producing oil and gas in California, Texas, and Louisiana. It owns oil and gas properties with principal operations in onshore California; offshore California; the Gulf Coast region, including Haynesville Shale, Eagle Ford Shale, and south and east Texas; the Mid-Continent region; and the Rocky Mountains. As of December 31, 2010, the company had estimated proved reserves of 416.1 million barrels of oil equivalent. Plains Exploration & Production Company was founded in 2002 and is headquartered in Houston, Texas.

Advisors' Opinion:

• [By Matt DiLallo]

  While it has diversity among metals, the company is also in the final stages of adding even more diversity among commodities. It has pending deals to acquire both McMoRan Exploration (NYSE: MMR  ) and Plains Exploration and Production (NYSE: PXP  ) . When the deals close, Freeport will shift its revenue mix from 100% mining related to around 75% mining and 25% oil and gas. That makes the company a truly diversified economic indicator as copper, oil, and natural gas are much more important to our economy than aluminum.

• [By Rich Duprey]

  Gold and copper miner�Freeport-McMoRan� (NYSE: FCX  ) has completed its acquisition of Plains Exploration & Production (NYSE: PXP  ) and, as previously planned, the board of directors says it will pay investors a supplemental dividend of $1.00 per share that is in addition to the regular quarterly payout of $0.3125 per share.

• [By David Smith]

  The pending purchases
  Aside from its current core metals operations, Freeport is in the process of acquiring a pair of independent oil and gas producers, Plains Exploration & Production (NYSE: PXP  ) and McMoRan Exploration (NYSE: MMR  ) . In December, Freeport announced that it would pay 0.6531 shares of its common stock and $25 in cash for each outstanding share of Plains. In addition, for McMoRan it stated that it would pay $14.75 in cash and 1.15 units of a royalty trust that will hold a 5% overriding royalty interest in McMoRan's shallow water and ultra-deepwater prospects.

Best Prefered Stocks To Invest In Right Now: China Ming Yang Wind Power Group Ltd (MY)

China Ming Yang Wind Power Group Limited incorporated on February 26, 2009, is a wind turbine manufacturer in China, focusing on designing, manufacturing, selling and servicing megawatt-class wind turbines. The Company�� products consist of basic models of wind turbines, each with a rated power capacity of 1.5 megawatt (MW); wind turbines with a rated power capacity of 2.0MW, and 2.5/3.0MW SCD wind turbines. Each product type may be installed with one of three rotor blade models depending on the location and wind conditions. As of December 31, 2012, the Company had entered into sales contracts with 37 end customers to deliver 3,730 units of its wind turbines.

It cooperates with aerodyn Energiesysteme to develop its 1.5 megawatt wind turbines and share intellectual property rights. It also has obtained licenses from aerodyn Asia Co., Ltd. (aerodyn Asia) to manufacture and distribute wind turbines utilizing its super-compact drive (SCD) technology, with a rated power capacity of 6.0MW.

The Company�� customers are the Chinese state-owned power producers which include Huaneng, China Datang, Huadian, China Guodian Corporation, and China Power Investment Corporation (CPIC) or their alternative energy subsidiaries, such as China Longyuan Power Group Corporation Limited (Longyuan), a subsidiary of Guodian, and China Datang Corporation Renewable Power Co., Limited (Datang Renewable), a subsidiary of China Datang. It also sells wind turbines to regional alternative energy investment companies, regional power producers and wind farm operators in the private sector. Its facilities are located in Zhongshan, Tianjin, Jilin, Rudong, Dali and Inner Mongolia in China.

The Company produces megawatt-class, grid-connected, horizontal-axis wind turbines, equipped with a double-fed constant frequency induction generator, which is a design of the generator that enables the generator to produce electric current of a constant frequency as the shaft rotates at varying speeds causing! the generator rotor to rotate at varying speed. It offers 1.5 megawatt turbines specially designed and developed for the wind and weather conditions and power grids in China. Its 1.5 megawatt wind turbines are equipped with rotor blades with a post-installation diameter of 77.1 meters, 82.6 meters or 89.0 meters.

The Company has license rights under a license agreement from aerodyn Asia to manufacture and distribute 2.5/3.0MW SCD wind turbines and 6.0MW SCD wind turbines in China. The Company is focused on developing 3.8MW wind turbine model for larger multi-megawatt wind turbines.

The Company competes with Sinovel, Goldwind, Dongfang Electric, United Power, Vestas, Gamesa Corporacion Tecnologica S.A. and GE Energy.

Advisors' Opinion:

• [By John Udovich]

  Small cap Ocean Power Technologies Inc (NASDAQ: OPTT) just sank 34% on news that they have fired their CEO "for cause,��meaning its worth taking a closer look at the stock to see if there is anything to salvage (shares were rising more than 6% in after hours) plus take a look at the performance of potential renewable energy related peers like Ormat Technologies, Inc (NYSE: ORA), Broadwind Energy Inc (NASDAQ: BWEN) and China Ming Yang Wind Power Group Ltd (NYSE: MY).

• [By Roberto Pedone]

  Another under-$10 stock that looks ready to trigger a big breakout trade is China Ming Yang Wind Power Group (MY), a wind turbine manufacturer in China. This stock has been very hot over the last six months, with shares up sharply by 52%.

  If you take a look at the chart for China Ming Yang Wind Power Group, you'll notice that this stock has been uptrending over the last few weeks, with shares moving higher from its low of $1.91 to its intraday high of $2.59 a share. During that uptrend, shares of MY have been consistently making higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of MY within range of triggering a big breakout trade.

  Market players should now look for long-biased trades in MY if it manages to break out above some past overhead resistance levels at $2.58 to $2.80 a share high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 1.56 million shares. If that breakout hits soon, then MY will set up to re-test or possibly take out its next major overhead resistance levels at $3.35 to its 52-week high at $3.52 a share. Any high-volume move above those levels will then give MY a chance to tag $4 a share.

  Traders can look to buy MY off weakness to anticipate that breakout and simply use a stop that sits right below its 50-day moving average of $2.30 a share, or near more support at $2.02 a share. One can also buy MY off strength once it starts to clear those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

Best Prefered Stocks To Invest In Right Now: (AUQ)

AuRico Gold Inc. engages in the exploration, development, and production of gold and silver projects and properties in Canada, Mexico, and Australia. Its principal property includes the Ocampo mine covering approximately 15,000 hectares located in Chihuahua State. The company was formerly known as Gammon Gold Inc. and changed its name to AuRico Gold Inc. in June 2011. AuRico Gold Inc. was founded in 1986 and is based in Toronto, Canada.

Advisors' Opinion:

• [By Garrett Cook]

  Basic materials sector was the top loser in the US market on Tuesday. Top decliners in the sector included Kraton Performance Polymers (NYSE: KRA), Molycorp (NYSE: MCP), and AuRico Gold (NYSE: AUQ).

Best Prefered Stocks To Invest In Right Now: Kirkland's Inc.(KIRK)

Kirkland?s, Inc. operates as a specialty retailer of home decor and gifts in the United States. Its stores offer various merchandise, including framed art, mirrors, wall decor, candles and related items, lamps, decorative accessories, accent furniture, textiles, garden-related accessories, and artificial floral products. The company?s stores also provide an assortment of holiday merchandise during seasonal periods, as well as items suitable for gift-giving. It operates stores under the Kirkland?s, Kirkland?s Home, Kirkland?s Home Outlet, and Kirkland?s Outlet names. The company operates its stores in enclosed malls and various off-mall venues, including lifestyle centers, power strip centers, outlet centers, and freestanding locations. Kirkland?s, Inc. also sells its products through its Web site kirklands.com. As of March 08, 2012, it operated 299 stores in 30 states. The company was founded in 1966 and is based in Nashville, Tennessee.

Advisors' Opinion:

• [By Seth Jayson]

  Calling all cash flows
  When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Kirkland's (Nasdaq: KIRK  ) , whose recent revenue and earnings are plotted below.

Best Prefered Stocks To Invest In Right Now: UPM-Kymmene Corporation (UPM1V)

UPM-Kymmene Corporation is a Finland-based paper and forest products company. The Company operates, along with its subsidiaries, in three segments: the Energy and Pulp segment is divided into three units: Energy, which includes the Company�� hydropower plant and shares in energy companies; Pulp, which includes the Company�� pulp mills, and Foster and Timber, which includes forests, wood procurement, sawmills and further processing; the Paper segment includes the Company�� paper mills, producing magazine paper, newsprint, fine papers, and specialty papers, and the Engineered materials segment is structured into two units: Label, which includes label-stock factories and slitting, and distribution terminals, and Plywood, which includes plywood mills. The Company�� other operations include the wood plastic composite unit, development units and logistic services. On October 2, 2013, it completed the sale of the wood processing mill in Aigrefeuille d'Aunis, to Groupe FP Bois. Advisors' Opinion:

• [By Corinne Gretler]

  UPM-Kymmene Oyj (UPM1V) fell 3.9 percent to 12.18 euros. UBS AG lowered Europe�� second-largest papermaker to sell from neutral. The brokerage said that demand for the company�� product will not recover in Europe and that the industry will probably reduce its capacity next year.

• [By Tom Stoukas]

  UPM-Kymmene (UPM1V), a rival maker of paper, dropped 1.9 percent to 10.23 euros.

  Aryzta surged 4 percent to 60.45 Swiss francs, the biggest gain since March 28. The owner of bakery brands including Delice de France and Otis Spunkmeyer posted full-year revenue of 4.5 billion euros ($6.1 billion), beating analysts��estimates of 4.43 billion euros. The company also forecast a double-digit percentage gain in 2014 earnings.

Best Prefered Stocks To Invest In Right Now: TruLan Resources Inc (TRLR)

Trulan Resources, Inc. (Trulan), incorporated on March 12, 1971, is a natural resource mineral exploration company. The Company�� focus is to locate and acquire mineral concessions and properties that have experienced various degrees of previous exploratory work where anomalous values of gold, silver and Platinum Group Metals (PGM��) projects in North and South America.

The IGP Project totals 885 Hectares (2,186 Acres) of wide spread mineralization and ore bodies that contain high grades of Iron, Gold, Platinum and high value industrial metals. There are eight known deposits in close proximity which have been tested to the point where an Indicated Ore resource has been delineated. There are four ore bodies with an Indicated Reserve in excess of 247 Million Metric Tons. Its Eureka Placer Claim is located on Eureka Creek in California�� Sierra City Mining District. This district covers a area in Sierra County, extending through Furnier, Loganville, Church Meadows, Gold Valley, and the Sierra City-Buttes areas.

Advisors' Opinion:

• [By Peter Graham]

  Small cap mining stocks Brazil Gold Corp (OTCMKTS: BRZG) and Trulan Resources (OTCMKTS: TRLR) were either active on the charts last week (in the case of the former) or recently the subject of paid promotions (in the case of the latter). However, mining is not exactly an easy business for a small and usually undercapitalized small cap mining stock given the amount it can cost to get a mine up and running. On the other hand, they could always be sitting on the next mother lode just waiting to come out of the ground. With that in mind, here is a quick reality check about these two small cap mining stocks:

Hot Solar Stocks To Invest In 2014

We have tracked the short interest in the following North American Solar companies as of September 13: Canadian Solar Inc. (NASDAQ: CSIQ), First Solar Inc. (NASDAQ: FSLR), GT Advanced Technologies Inc. (NASDAQ: GTAT), SunEdison Inc. (NYSE: SUNE) and SunPower Corp. (NASDAQ: SPWR).

In the Chinese solar sector we tracked the following short interest changes: JA Solar Holdings Co. Ltd. (NASDAQ: JASO), LDK Solar Co. Inc. (NYSE: LDK), Suntech Power Holdings Co. Ltd. (NYSE: STP), Trina Solar Ltd. (NYSE: TSL) and Yingli Green Energy Holding Co. Ltd. (NYSE: YGE).�For China-based firms, the percentage of shares short is not available because the companies are also listed on other exchanges.

Canadian Solar Inc. (NASDAQ: CSIQ) saw short interest rise by 5.7% to 3.49 million shares, about 5.7% of the company�� total float.

First Solar Inc. (NASDAQ: FSLR) short interest dropped by 3.8% to 10.78 million shares, which represents 15.3% of the company�� float.

GT Advanced Technologies Inc. (NASDAQ: GTAT) showed a decrease of 3.9% in short interest to 37.98 million shares, about 31.1% of GT�� float.

Hot Logistics Companies To Watch In Right Now: DAQQ New Energy Corp.(DQ)

Daqo New Energy Corp., together with its subsidiaries, manufactures and sells polysilicon in China. The company sells its polysilicon to photovoltaic product manufacturers for use in the processing of ingots, wafers, cells and modules for solar power solutions. It also produces and sells mono-crystalline and multi-crystalline modules to photovoltaic system integrators and distributors in China and internationally under its Daqo brand. The company was formerly known as Mega Stand International Limited and changed its name to Daqo New Energy Corp. in August 2009. Daqo New Energy Corp. was founded in 2006 and is headquartered Wanzhou, the People?s Republic of China.

Advisors' Opinion:

• [By Ali Berri]

  In trading on Friday, energy shares were relative leaders, up on the day by about 0.42 percent. Meanwhile, top gainers in the sector included Daqo New Energy (NYSE: DQ), up 9.4 percent, and Goodrich Petroleum (NYSE: GDP), up 6.2 percent.
  

• [By Lisa Levin]

  Daqo New Energy (NYSE: DQ) shares gained 12.78% to $33.58 on quarterly results.

  SINA (NASDAQ: SINA) rose 7.26% to $51.29 after the company reported upbeat quarterly results.

Hot Solar Stocks To Invest In 2014: First Solar Inc.(FSLR)

First Solar, Inc. manufactures and sells solar modules using a thin-film semiconductor technology. It also designs, constructs, and sells photovoltaic solar power systems. The company?s solar modules employ a thin layer of semiconductor material to convert sunlight into electricity. Its integrated solar power systems activities include the project development; engineering, procurement, and construction services; operating and maintenance services; and project finance. The company sells solar modules to project developers, system integrators, and operators of renewable energy projects; and solar power systems to investor owned utilities, independent power developers and producers, and commercial and industrial companies, as well as other system owners. It operates in the United States, Germany, France, Canada, and internationally. The company was formerly known as First Solar Holdings, Inc. and changed its name to First Solar, Inc. in 2006. First Solar was founded in 1999 a nd is headquartered in Tempe, Arizona.

Advisors' Opinion:

• [By Seth Jayson]

  First Solar (Nasdaq: FSLR  ) is expected to report Q1 earnings around May 2. Here's what Wall Street wants to see:

  The 10-second takeaway
  Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict First Solar's revenues will grow 46.1% and EPS will turn positive

• [By Chad Fraser]

  Correspondingly, many solar stocks soared in 2013; the Market Vectors Solar Energy ETF (NYSE: KWT), a reasonable proxy for the industry, surged 103.5 percent on the year, far eclipsing the S&P 500�� 31.8 percent climb.
  
  That outperformance has continued into 2014, with the ETF tacking on a 19.9 percent gain year-to-date, compared to 6.8 percent for the S&P 500.
  
  The rebound comes after a tough few years for the solar industry. First, the financial crisis deterred customers and drove down sales. Then governments cut spending to rein in their deficits��ncluding on solar power subsidies. This all came against a glut of cheap panels��ainly from Chinese manufacturers��hat lowered panel prices and profit margins.
  
  Today, solar stocks continue to be volatile, and the industry is still subject to unpredictable swings in supply and demand, as well as constantly shifting political winds.
  
  It�� also dealing with strong competition from natural gas, as higher U.S. production has put downward pressure on prices. Last year in the U.S., for example, gas accounted for just over 50% of new utility-scale generating capacity, according to the Energy Information Administration, with solar accounting for 22%��hough that was up from just 6% in 2012.
  
  However, there are signs that solar is making progress on this front. For example, the REN21 report noted that solar power is now competitive with fossil fuels without subsidies in at least 19 markets in 15 countries.
  
  A Large-Scale Solar Developer to Watch
  
  One solar stock that currently carries a buy rating in The Energy Strategist�� Growth Portfolio is First Solar (NasdaqGS: FSLR), which focuses on large, utility-scale solar projects.
  
  First Solar started up as a pure photovoltaic module maker in 1999 but in 2011 began shifting toward building, financing, maintaining and selling solar facilities. The company benefits from its vertically integrated structure, because

• [By Michael Cintolo]

  Solar-sector leader First Solar (FSLR) has been riding high in the wake of its strong third-quarter earnings report. The firm crushed estimates, with revenue up 51% and earnings jumping 80%.

Hot Solar Stocks To Invest In 2014: Real Goods Solar Inc.(RSOL)

Real Goods Solar, Inc. operates as a residential and commercial solar energy integrator primarily in California and Colorado. The company provides engineering, procurement, and construction services. It offers various turnkey solar energy services, including design, procurement, permitting, build-out, grid connection, financing referrals, and warranty and customer satisfaction services. The company installs residential and small commercial systems that range between 3 kilowatts and 1 megawatt output. It also engages in the retail sale of renewable energy products. The company was founded in 1978 and is based in Louisville, Colorado.

Advisors' Opinion:

• [By Bryan Murphy]

  If you were lucky enough to be in an American Community (OTCMKTS:ACYD) position anytime before October 8th, then congratulations - you're up big. Now get out. Instead, use freed-up that capital to take on a position in Real Goods Solar, Inc. (NASDAQ:RSOL), which looks like it's at the beginning of a good-sized rally.

• [By Bryan Murphy]

  My enthusiasm regarding Real Goods Solar, Inc. (NASDAQ:RSOL) and Westinghouse Solar Inc. (OTCMKTS:WEST) hasn't exactly been a veiled secret. Though I've favored one over the other at various times since the entire solar panel industry went back into high gear in the middle of the second quarter, I've been a fan of both RSOL as well as WEST for a while. The trick has been finding the right entry spot for both of these volatile stocks.

• [By Bryan Murphy]

  Three weeks ago, I recommended Real Goods Solar, Inc. (NASDAQ:RSOL) as a buy. Though the stock was still drifting in the shadow of a huge May pullback - from a high of $7.17 to a low of $2.13 by mid-June - RSOL was finding some support at key moving average lines, and even pushing up and off of them. Not many of you (and I'm using "you" interchangeably with "investors in general") seemed to care. So why am I looking at Real Goods Solar again now? Because, with competitors LDK Solar Co., Ltd (NYSE:LDK) and ReneSola Ltd. (NYSE:SOL) seeing their shares surge today, odds are good RSOL is going to get swept up in that move. Real Goods Solar shares are a better bet, however, in that - unlike SOL and LDK - they aren't overbought yet.

Hot Solar Stocks To Invest In 2014: Ascent Solar Technologies Inc.(ASTI)

Ascent Solar Technologies, Inc., a development stage company, focuses on commercializing flexible photovoltaic (PV) modules using its proprietary technology. The company intends to manufacture roll-format PV modules that use copper-indium-gallium-diselenide (CIGS) on a plastic substrate. Its proprietary manufacturing process deposits multiple layers of materials, including a thin-film of CIGS semiconductor material on a plastic substrate and laser patterns the layers to create interconnected PV cells or PV modules through monolithic integration process. The company would serve the building applied photovoltaic (BAPV) and building integrated photovoltaic (BIPV) market, as well as specialty markets, such as defense, portable power, transportation, electronic integrated photovoltaic, and space and near-space. It has a strategic relationship with Norsk Hydro Produksjon AS to access customers in the BIPV/BAPV markets worldwide. Ascent Solar Technologies, Inc. was founded in 200 5 and is based in Thornton, Colorado.

Advisors' Opinion:

• [By John Udovich]

  Solar stocks have not exactly given buy and hold investors a smooth ride, but small cap�GT Advanced Technologies Inc (NASDAQ: GTAT) could be an interesting materials play on the solar sector���meaning its worth taking a closer look at the stock along with potential peers like Ascent Solar Technologies, Inc (NASDAQ: ASTI) and STR Holdings, Inc (NYSE: STRI) plus solar ETF Guggenheim Solar ETF (NYSEARCA: TAN). I should mention that just last week, we added GT Advanced Technologies to our�SmallCap Network Elite Opportunity (SCN EO) portfolio for both�fundamentals and technical reasons and we are already up almost 9%.

Hot Solar Stocks To Invest In 2014: LDK Solar Co. Ltd.(LDK)

LDK Solar Co., Ltd., together with its subsidiaries, engages in the design, development, manufacture, and marketing of photovoltaic (PV) products; and development of power plant projects. It offers solar-grade and semiconductor-grade polysilicon; and multicrystalline and monocrystalline solar wafers to the manufacturers of solar cells and solar modules. The company also provides wafer processing services to monocrystalline and multicrystalline solar cell and module manufacturers; and sells silicon materials, such as ingots and polysilicon scraps. In addition, it engages in the production and sale of solar cells and modules to developers, distributors, and system integrators; and design and development of solar power projects in Europe, the United States, and China, as well as provides engineering, procurement, and construction services. LDK Solar Co., Ltd. operates in Europe, the Asia Pacific, and North America. The company was founded in 2005 and is based in Xinyu City, t he People?s Republic of China.

Advisors' Opinion:

• [By Brian Pacampara]

  Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, solar wafer maker LDK Solar (NYSE: LDK  ) has received the dreaded one-star ranking.

• [By Travis Hoium]

  What: After a two-day run-up in solar stocks, the party ended quickly, and every stock in the industry is dropping like a rock. Suntech Power (NYSE: STP  ) led the declines by falling 23%, and LDK Solar (NYSE: LDK  ) , Yingli Green Energy (NYSE: YGE  ) , and JA Solar (NASDAQ: JASO  ) all dropped at least 15%.

Hot Solar Stocks To Invest In 2014: JinkoSolar Holding Company Limited(JKS)

JinkoSolar Holding Co., Ltd., together with its subsidiaries, engages in the manufacture and sale of solar power products in China and internationally. The company provides solar modules, silicon wafers and ingots, and solar cells, as well as processing services, including silicon wafer tolling services. It sells its products under the JinkoSolar brand name. The company?s customers include distributors, project developers, and system integrators. It trades its products under short-term contracts and by spot market sales. The company also produces accessory materials for solar power products, such as solar aluminum frame, solar junction box, aluminum materials windows, and other metal component parts. JinkoSolar Holding Co., Ltd. was founded in 2006 and is based in Shangrao, the People?s Republic of China.

Advisors' Opinion:

• [By Jayson Derrick]

  JinkoSolar (NYSE: JKS) received a total of $225 million investment for downstream projects from the China Development Bank International, Macquarie Greater China and New Horizon Capital. Shares lost 1.20 percent, closing at $26.25.

• [By Monica Gerson]

  Analysts are expecting JinkoSolar Holding Co (NYSE: JKS) to have earned $0.76 per share on revenue of $391.55 million in the second quarter. JinkoSolar shares gained 1.73% to $28.30 in after-hours trading.